/CORT

CORT Stock - Corcept Therapeutics Incorporated

Q: What is the analyst price target for CORT?

Analyst price target information is not currently available for CORT.

Q: What is CORT's market cap?

Market capitalization information is not currently available for CORT.

Healthcare|Biotechnology|NASDAQ

$36.35-2.70%

$1.01 (-2.70%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+100.3%upside

Target: $72.81

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for CORT

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.23

52W High$117.33

52W Low$32.99

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$675.04M	$482.38M	$401.86M	$365.98M	$353.87M
Gross Profit	$664.16M	$475.89M	$396.47M	$360.70M	$348.29M
Gross Margin	98.4%	98.7%	98.7%	98.6%	98.4%
Operating Income	$136.95M	$107.28M	$112.63M	$124.48M	$128.20M
Net Income	$139.73M	$106.14M	$101.42M	$112.51M	$106.01M
Net Margin	20.7%	22.0%	25.2%	30.7%	30.0%
EPS	$1.35	$1.02	$0.95	$0.97	$0.92

Company Overview

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Visit Website

Earnings History & Surprises

CORT

Beat Rate

61%

Last 18 quarters

Avg Surprise

+11.3%

EPS vs Estimate

Beats / Misses

11/5

2 met exactly

Latest EPS

$0.16

Q4 2025

EPS Surprise History

Q1 24

+7.7%

$0.28vs$0.26

Q2 24

+13.6%

$0.25vs$0.22

Q3 24

+39.1%

$0.32vs$0.23

Q4 24

+46.4%

$0.41vs$0.28

Q1 25

-29.7%

$0.26vs$0.37

Q2 25

0.0%

$0.17vs$0.17

Q3 25

+26.1%

$0.29vs$0.23

Q4 25

-11.1%

$0.16vs$0.18

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 4, 2026	—	—	—	—
Q1 2026	Feb 25, 2026	$0.27	—	—	—
Q4 2025	Nov 4, 2025	$0.18	$0.16	-11.1%	✗ MISS
Q3 2025	Jul 31, 2025	$0.23	$0.29	+26.1%	✓ BEAT
Q2 2025	May 5, 2025	$0.17	$0.17	0.0%	= MET
Q1 2025	Feb 26, 2025	$0.37	$0.26	-29.7%	✗ MISS
Q4 2024	Oct 30, 2024	$0.28	$0.41	+46.4%	✓ BEAT
Q3 2024	Jul 29, 2024	$0.23	$0.32	+39.1%	✓ BEAT
Q2 2024	May 1, 2024	$0.22	$0.25	+13.6%	✓ BEAT
Q1 2024	Feb 15, 2024	$0.26	$0.28	+7.7%	✓ BEAT
Q4 2023	Nov 1, 2023	$0.22	$0.28	+27.3%	✓ BEAT
Q3 2023	Aug 2, 2023	$0.15	$0.25	+66.7%	✓ BEAT
Q2 2023	May 3, 2023	$0.19	$0.14	-26.3%	✗ MISS
Q1 2023	Feb 28, 2023	$0.23	$0.14	-39.1%	✗ MISS
Q4 2022	Nov 3, 2022	$0.23	$0.30	+30.4%	✓ BEAT
Q3 2022	Aug 3, 2022	$0.24	$0.24	0.0%	= MET
Q2 2022	May 5, 2022	$0.24	$0.20	-16.7%	✗ MISS
Q1 2022	Feb 15, 2022	$0.22	$0.26	+18.2%	✓ BEAT
Q4 2021	Nov 3, 2021	$0.20	$0.24	+20.0%	✓ BEAT
Q3 2021	Jul 29, 2021	$0.16	$0.21	+31.2%	✓ BEAT

Frequently Asked Questions about CORT

What is CORT's current stock price?

Corcept Therapeutics Incorporated (CORT) is currently trading at $36.35 per share. The stock has moved -2.70% today.

What is the analyst price target for CORT?

The average analyst price target for CORT is $72.80, based on 1 analyst.

What sector is Corcept Therapeutics Incorporated in?

Corcept Therapeutics Incorporated operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is CORT's market cap?

Corcept Therapeutics Incorporated has a market capitalization of $3.82 billion, making it a mid-cap company.

Does CORT pay dividends?

No, Corcept Therapeutics Incorporated does not currently pay a dividend to shareholders.